HC Wainwright Issues Positive Forecast for Intensity Therapeutics (NASDAQ:INTS) Stock Price

Intensity Therapeutics (NASDAQ:INTS) had its target price raised by equities researchers at HC Wainwright from $5.00 to $7.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 62.04% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. Finally, Benchmark reiterated a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Intensity Therapeutics has an average rating of “Moderate Buy” and an average price target of $22.25.

Intensity Therapeutics Stock Performance

Shares of Intensity Therapeutics stock traded up $0.17 during trading on Tuesday, hitting $4.32. 6,368 shares of the company’s stock were exchanged, compared to its average volume of 43,093. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The business has a 50-day simple moving average of $4.26 and a 200-day simple moving average of $5.48. Intensity Therapeutics has a 52-week low of $3.51 and a 52-week high of $43.50. The stock has a market capitalization of $14.08 million, a price-to-earnings ratio of -0.76 and a beta of 2.76.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.24). On average, research analysts forecast that Intensity Therapeutics will post -2.7 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in shares of Intensity Therapeutics in the fourth quarter worth about $26,000. Corient Private Wealth LLC purchased a new stake in shares of Intensity Therapeutics during the 4th quarter worth about $41,000. State Street Corp grew its position in shares of Intensity Therapeutics by 839.3% during the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after acquiring an additional 121,700 shares during the period. Legacy Advisors LLC acquired a new stake in shares of Intensity Therapeutics during the 4th quarter valued at about $63,000. Finally, Mesirow Financial Investment Management Inc. increased its stake in shares of Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after purchasing an additional 51,000 shares in the last quarter. Hedge funds and other institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.